ACXP - Acurx Pharmaceuticals Inc. (ACXP) CEO David Luci on Q3 2021 Earnings Call Transcript

Acurx Pharmaceuticals, Inc. (ACXP) Q3 2021 Earnings Conference Call Nov 15, 2021 08:30 AM ET Company Participants David Luci - President and CEO Robert Shawah - Co-Founder and CFO Conference Call Participants Jason McCarthy - Maxim Group Presentation Operator [Technical Difficulty] David Luci Thank you, Rob and good morning to everyone and thank you for joining us on this morning's conference call to discuss Acurx's Financial Results. During today's call, we'll review our financial results for the quarter and nine months ended September 30, 2021 as well as some key corporate highlights, and then we'd be pleased to take any questions. In the third quarter, we continued on our critical path forward initiating our Phase 2b be clinical trial of our lead antibiotic candidate, ibezapolstat in patients with C. difficile infection. In total, we have activated 12 clinical trial sites and we anticipate enrollment to begin this month. Our clinical

For further details see:

Acurx Pharmaceuticals, Inc. (ACXP) CEO David Luci on Q3 2021 Earnings Call Transcript